生物技术公司Cytokinetics（CYTK）周二盘后股价大涨5.94%，主要受益于该公司公布的第一季度财报中营收数据远超分析师预期。
根据公司发布的财报，截至3月31日的季度内，Cytokinetics实现营收158万美元，同比大幅增长89.1%，远超分析师预期的120万美元。尽管调整后每股亏损1.39美元略高于预期的1.38美元，但强劲的营收增长似乎成为推动股价上涨的主要因素。
值得注意的是，尽管Cytokinetics过去几个季度的盈利表现未达预期，但华尔街分析师对公司前景仍保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，其中19个为"强烈买入"或"买入"，3个为"持有"，没有"卖出"或"强烈卖出"评级。分析师给予Cytokinetics未来12个月的目标价中位数为75.00美元，显示出对公司长期发展的信心。这一积极展望可能也是支撑股价上涨的另一个重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.